首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1361106

HIV 诊断与治疗：全球市场

Diagnostics and Therapeutics for HIV: Global Markets

出版日期: 2023年10月10日 | 出版商:

BCC Research | 英文 186 Pages | 订单完成后即时交付

价格

简介目录图表

全球爱滋病毒诊断和治疗市场规模预计将从2023年的304亿美元成长到年终的393亿美元，预测期内年复合成长率为5.3%。

以抗爱滋病毒药物类别划分，单锭方案（STR）/固定剂量组合药物（FDC）药物部门将从 2023 年的 113 亿美元成长，同期年复合成长率为 5.8%，到年终。预计将成长至149 亿美元。此外，核苷酸逆转录酶抑制剂（NRTI）部门预计将从2023年的89亿美元成长到年终的110亿美元，年复合成长率为4.4%。

本报告调查了全球爱滋病毒诊断和治疗市场，提供了市场和技术概述、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场和地区的详细分析以及技术，并总结了专利趋势、ESG 发展、竞争形势以及主要企业概况。

全球市场预测
区域市场
北美洲
市场分析/预测
流行病学
HIV 检测与建议
北美市场相关法规
欧洲爱滋病药物市场
市场分析/预测
流行病学
HIV 检测与建议
影响欧洲爱滋病毒市场的法规
亚太地区爱滋病治疗市场
东南亚地区
西太平洋地区
预防和筛检计划
亚太地区爱滋病市场的法规
仿製药製造商对市场的影响
市场分析/预测
其他地区爱滋病药物市场
非洲地区
全球爱滋病毒市场投资

第6章HIV 市场：依 ARV 药物类别

概述
治疗时间表
一线治疗方案
二线治疗方案
三线治疗方案
市场概览：依药品类别
核苷/核苷酸逆转录酶抑制剂 (NRTI)
蛋白酶抑制剂 (PI)
单片方案 (STR)/固定剂量组合药物(FDC) 药物
整合酶链转移抑制剂 (INSTI)
非核苷酸逆转录酶抑制剂 (NNRTI)
进入抑制剂

第7章新兴技术

概述
分子诊断
下一代定序（NGS）
即时检测
AI
其他的

第8章HIV 诊断市场评估

HIV 诊断市场：按测试类型
HIV检测的演变
基于抗原和抗体的测试
前景
CD4测试
病毒负担测试
HIV 诊断产品简介：依测试类型
CD4检测产品
病毒量检测产品

第9章专利

第10章竞争形势

併购/合作

第11章公司简介

ABBOTT
ASTRAZENECA
B. BRAUN SE
BECTON, DICKINSON AND COMPANY
BIOCON
BIO-RAD LABORATORIES INC.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DANAHER CORP.
DEXCOM INC.
INSULET CORP.
JOHNSON & JOHNSON SERVICES INC.
LIFESCAN IP HOLDINGS LLC
LILLY
MEDTRONIC
MERCK & CO. INC.
NOVA BIOMEDICAL
NOVARTIS AG
NOVO NORDISK A/S
QIAGEN NV
ROCHE (F. HOFFMANN-LA ROCHE LTD.)
SANOFI
SIEMENS HEALTHINEERS AG
TERUMO CORP.
THERMO FISHER SCIENTIFIC INC.
YPSOMED AG

简介目录图表

Product Code: PHM058D

Highlights:

The global market for HIV diagnostics and therapeutics is expected to increase from $30.4 billion in 2023 to $39.3 billion by the end of 2028, with compound annual growth rate (CAGR) of 5.3% during the forecast period of 2023-2028.

Single-tablet regimen FDC market for HIV diagnostics and therapeutics is expected to increase from $11.3 billion in 2023 to $14.9 billion by the end of 2028, at a CAGR of 5.8 during the forecast period of 2023-2028.

Nucleoside reverse transcriptase inhibitors market for HIV diagnostics and therapeutics is expected to increase from $8.9 billion in 2023 to $11.0 billion by the end of 2028, at a CAGR of 4.4% during the forecast period of 2023-2028.

Report Scope:

This report organizes information from diverse sources into sections such as an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements, and patents. The scope of this report includes an overview of the global market scenario for the diagnosis and treatment of HIV, with base year data from 2022, estimations for 2023 and forecasts for 2028 that are derived using projections of CAGR during the forecast period. Market value data is provided at global, regional, and country levels for treatments by drug categories. Market data for HIV diagnostics is provided for regional levels, with details on test types. Estimated values are based on companies' total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

The report forecasts the global market for HIV therapeutics by drug class. It discusses market data for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combination (STR FDC), HIV integrase strand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The enzyme inhibitor drug class has been excluded when calculating the global HIV therapeutics market, as there are no late-stage pipeline molecules.

Diagnostic tests such as antigen- and antibody-based tests, CD4 tests and viral load tests are detailed with current and forecasted market data. Antigen- and antibody-based tests cover enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests, and NAT tests; CD4 tests include tests conducted to monitor the CD4 load; and viral load tests include all PCR-based tests.

A detailed analysis illustrating market dynamics and market structure is incorporated into the report. A Porter's Five Forces analysis and the supply and distribution chain are discussed in detail to provide an in-depth understanding of this market. The report covers the current regulations and guidelines for diagnostics and therapeutics for HIV, and it provides a survey of the top market players, detailing their business operations, segment focus, revenue, and strategy analysis. The report also features a market share analysis of these leading players, including information about product launches and pipeline products.

In terms of geography, the report analyzes the market across the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). Key countries like the U.S., Canada, Mexico, Germany, France, UK, Italy, China, India and Japan are given special focus due to the high concentration of HIV diagnostics and therapeutics manufacturing companies and contract manufacturing organizations located in these areas.

The base year for the market data in this report is 2022, historical data is provided for 2020 and forecast data is given for 2028. Historical, base year and forecast data are provided for each market segment of the report.

Report Includes:

27 data tables and 41 additional tables
An overview of the global markets for diagnostics and therapeutics for HIV
An estimate of the market's size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Quantification of the market potential of diagnostics and therapeutics for HIV by drug category, diagnostic test type, and region
Coverage of HIV timeline and milestones, HIV life cycle, its treatment and mechanism of action, and description of HIV prophylaxis
Evaluation of market dynamics such as drivers and restraints, current industry trends and patterns, and an assessment of the cost implications for treatments in many countries
Information on regional awareness programs, WHO initiatives and development of novel therapies, and discussion on rising comorbidities in HIV patients and social stigma associated with STDs
Coverage of ongoing research and predictions of the market's future direction
Insights into the regulatory scenario for the U.S., Europe and Japan, to provide an overview of the regulations for new drug launches and diagnostic kits
Descriptions of the competitive landscape, product mapping, the strategic initiatives of the leading companies, including their R&D activities
Profiles of the key companies, including Medtronic, Abbott, Sanofi, Roche, Bio-Rad Laboratories Inc., and Danaher Corp.

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
What's New in This Update?
Scope of Report
Information Sources and Methodology
Secondary Research
Primary Research
Research Methodology
Geographic Breakdown

Chapter 2 Summary and Highlights

Overview
Market Outlook

Chapter 3 Market and Technology Background

Overview of Human Immunodeficiency Virus (HIV)
Report Overview
Disease Prognosis
Symptoms
Treatments
HIV Timeline and Milestones
HIV Life Cycle: Treatment and Mechanism of Action
HIV Prophylaxis
Pre-exposure Prophylaxis (PrEP)
Post-exposure Prophylaxis (PEP)
Drug Resistance
Medication Adherence
WHO Initiatives

Chapter 4 Global Industry Trends

Trends in Global HIV Transmission
Regional Awareness Programs
Development of Novel Therapies
Public-Private Partnerships
Rising Comorbidities in HIV Patients with an Increase in the Longevity of Patients
Global Programs to Counter HIV
Preventing Transmission from Mother to Child
Challenges
Underestimating the Risk of Contracting the Disease
Social Stigma Associated with STDs
High Cost of Treatment

Chapter 5 Market Breakdown by HIV Therapeutic

Global Market Forecast for HIV Therapeutics
Regional Markets for HIV Therapeutics
North America
Market Analysis and Forecast
Epidemiology
HIV Testing and Recommendations
Regulation of the North American Market for HIV Therapeutics
European Market for HIV Therapeutics
Market Analysis and Forecast
Epidemiology
HIV Testing and Recommendations
Regulations Impacting the European HIV Market
Asia-Pacific Market for HIV Therapeutics
Southeast Asian Regions
Western Pacific Regions
Prevention and Screening Programs
Regulation of the Asia-Pacific HIV Market
Market Impact of Generic Manufacturers
Market Analysis and Forecast
Rest of the World (RoW) Market for HIV Therapeutics
African Region
Global Investments in the HIV Market

Chapter 6 HIV Market by ARV Drug Category

Overview
Timeline of Therapies
First-Line Treatment Regimen
Second-Line Treatment Regimen
Third-Line/Salvage Treatment Regimen
Market Overview by Drug Category
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Protease Inhibitors (PIs)
Single-Tablet Regimen (STR)/Fixed-Dose Combination (FDC) Drugs
Integrase Strand Transfer Inhibitors (INSTI)
Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTIs)
Entry Inhibitors

Chapter 7 Emerging Technologies

Overview
Molecular Diagnostics
Next-Generation Sequencing (NGS)
Point-of-Care Testing
Artificial Intelligence (AI)
Other Emerging Techniques

Chapter 8 Evaluation of Market for HIV Diagnostics

Market for HIV Diagnostics by Test Type
Evolution of HIV Tests
Antigen- and Antibody-Based Tests
Future Perspective
CD4 Testing
Viral Load Testing
HIV Diagnostic Product Profiles by Test Type
CD4 Testing Products
Viral Load Testing Products

Chapter 9 Patents

Overview

Chapter 10 Competitive Landscape

Mergers, Acquisitions and Collaborations

Chapter 11 Company Profiles

ABBOTT
ASTRAZENECA
B. BRAUN SE
BECTON, DICKINSON AND COMPANY
BIOCON
BIO-RAD LABORATORIES INC.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DANAHER CORP.
DEXCOM INC.
INSULET CORP.
JOHNSON & JOHNSON SERVICES INC.
LIFESCAN IP HOLDINGS LLC
LILLY
MEDTRONIC
MERCK & CO. INC.
NOVA BIOMEDICAL
NOVARTIS AG
NOVO NORDISK A/S
QIAGEN N.V.
ROCHE (F. HOFFMANN-LA ROCHE LTD.)
SANOFI
SIEMENS HEALTHINEERS AG
TERUMO CORP.
THERMO FISHER SCIENTIFIC INC.
YPSOMED AG

简介目录图表

List of Tables

Summary Table : Global Market for HIV Diagnostics and Therapeutics, by Drug Category, Through 2028
Table 1 : Milestones in the History of HIV
Table 2 : Life Cycle of HIV Therapeutics Target Points
Table 3 : Global Market for HIV Therapeutics, by Drug Category, Through 2028
Table 4 : Global Market for HIV Therapeutics, by Region, Through 2028
Table 5 : Generic Drug Manufacturers in the Asia-Pacific Region
Table 6 : WHO Recommendations for ART Treatment
Table 7 : Approved NRTIs, 2022
Table 8 : Approved Generic NRTIs, 2022
Table 9 : Global Market for NRTIs, by Region, Through 2028
Table 10 : Approved PIs, 2022
Table 11 : Approved Generic PIs, 2022
Table 12 : Global Market for Protease Inhibitors, by Region, Through 2028
Table 13 : Approved STRs, 2022
Table 14 : Approved STR FDC Generics, 2022
Table 15 : Global Market for Single-Tablet Regimen FDC, by Region, Through 2028
Table 16 : FDA Approved INSTIs, 2022
Table 17 : Global Market for INSTIs, by Region, Through 2028
Table 18 : Approved NNRTIs, 2022
Table 19 : Approved Generic NNRTIs, 2022
Table 20 : Global Market for NNRTIs, by Region, Through 2028
Table 21 : Approved Entry Inhibitors, 2022
Table 22 : Global Market for HIV Diagnostics, by Region, Through 2028
Table 23 : Global Market for HIV Diagnostics, by Test Type, Through 2028
Table 24 : Antibody HIV Tests, 2022
Table 25 : FDA Approved Antigen-Antibody Combo Tests, 2012
Table 26 : Point-of-Care CD4 Tests
Table 27 : Viral Load Tests
Table 28 : Select Patent Applications Filed on HIV Diagnostics and Therapeutics, 2023
Table 29 : M&A Activity among Diagnostics and Therapeutics Manufacturing Companies, 2023
Table 30 : Abbott: Financials, 2019-2022
Table 31 : Abbott: Product Portfolio, by Business Segment
Table 32 : Abbott: Recent Developments, 2023
Table 33 : AstraZeneca: Financial Performance, 2020-2022
Table 34 : AstraZeneca: Selected Key Developments, 2023
Table 35 : Braun: Financials, 2021
Table 36 : Becton, Dickinson and Company: Company Financials, 2022
Table 37 : Becton, Dickinson and Company: Product Portfolio
Table 38 : Biocon: Selected Key Developments, 2022
Table 39 : Bio-Rad Laboratories Inc.: Company Financials, 2022
Table 40 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 41 : Boehringer Ingelheim: Selected Key Developments, 2023
Table 42 : Danaher Corp.: Company Financials, 2022
Table 43 : Danaher Corp.: Product Portfolio
Table 44 : Dexcom: Financials, 2021 and 2022
Table 45 : Insulet Corp.: Revenue, by Segment, 2020-2022
Table 46 : Johnson & Johnson: Financials, 2022
Table 47 : Johnson & Johnson: Recent Developments and Strategies, 2017-2022
Table 48 : Lilly: Financial Performance, 2018-2021
Table 49 : Lilly: Key Developments, 2023
Table 50 : Medtronic: Financials, 2020-2022
Table 51 : Medtronic: Product Portfolio
Table 52 : Medtronic: Patient Monitoring Device Product Portfolio
Table 53 : Medtronic: Recent Developments, 2015-2022
Table 54 : Merck & Co. Inc.: Financial Performance, 2020-2022
Table 55 : Novartis: Key Financials, 2021-2022
Table 56 : Novartis Key Developments, 2022
Table 57 : Novo Nordisk: Key Financials, 2021-2022
Table 58 : Novo Nordisk: Selected Key Developments, 2023
Table 59 : Qiagen: Product Portfolio
Table 60 : Roche: Financials, 2021-2022
Table 61 : Roche: Revenue, by Business Segment, 2021 and 2022
Table 62 : Roche: Product Portfolio
Table 63 : Roche: Recent Developments, 2023
Table 64 : Sanofi: Business Segment
Table 65 : Sanofi: Financial Performance, 2021 and 2022
Table 66 : Sanofi: Key Developments, 2023
Table 67 : Siemens Healthineers AG: Product Portfolio

List of Figures

Summary Figure : Global Market for HIV Diagnostics and Therapeutics, 2020-2028
Figure 1 : Types of Drug Failure Encountered During HIV Treatment
Figure 2 : Summary of the Global HIV Epidemic, 2022
Figure 3 : Global Market for HIV Therapeutics, 2020-2028
Figure 4 : Global Market Shares of HIV Therapeutics, by Drug Category, 2022
Figure 5 : Global Market for HIV Therapeutics, by Region, 2020-2028
Figure 6 : Number of People Living with HIV Globally, by Region, 2010-2022
Figure 7 : North American Market for HIV Therapeutics, 2020-2028
Figure 8 : HIV Diagnoses in the U.S., by Transmission Category, 2021
Figure 9 : European Market for HIV Therapeutics, 2020-2028
Figure 10 : European Market for HIV Therapeutics, by Country, 2020-2028
Figure 11 : Asia-Pacific Market for HIV Therapeutics, 2020-2028
Figure 12 : Asia-Pacific Market for HIV Therapeutics, by Country, 2020-2028
Figure 13 : Rest of the World Market for HIV Therapeutics, 2020-2028
Figure 14 : Treatment Switching
Figure 15 : Global Market for NRTIs, 2020-2028
Figure 16 : Global Market for NRTIs, by Region, 2020-2028
Figure 17 : Global Market for Protease Inhibitors, 2020-2028
Figure 18 : Global Market for Protease Inhibitors, by Region, 2020-2028
Figure 19 : Global Market for Single-Tablet Regimen, 2020-2028
Figure 20 : Global Market for Single-Tablet Regimen FDC, by Region, 2020-2028
Figure 21 : Global Market for INSTIs, 2020-2028
Figure 22 : Global Market for INSTIs, by Region, 2020-2028
Figure 23 : Global Market for NNRTIs, 2020-2028
Figure 24 : Global Market for NNRTIs, by Region, 2020-2028
Figure 25 : HIV Diagnostics Test Types, by Category
Figure 26 : Global Market for HIV Diagnostics, 2020-2028
Figure 27 : Abbott: Revenue Share, by Country/Region, 2021 and 2022
Figure 28 : Abbott: Revenue Share, by Business Segment, 2021 and 2022
Figure 29 : AstraZeneca: Sales Share, by Segment, 2022
Figure 30 : AstraZeneca: Revenue Share, by Region/Country, 2022
Figure 31 : Braun: Revenue, 2015-2021
Figure 32 : Braun: Revenue Share, by Country/Region, 2021
Figure 33 : Braun: Revenue Share, by Segment, 2021
Figure 34 : Becton, Dickinson and Company: Revenue Share, by Business Segment, 2022
Figure 35 : Becton, Dickinson and Company: Revenue Share, by Region/Country, 2022
Figure 36 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Segment, 2022
Figure 37 : Bio-Rad Laboratories Inc.: Revenue Share, by Region/Country, 2022
Figure 38 : Boehringer Ingelheim: Annual Revenue, 2021 and 2022
Figure 39 : Boehringer Ingelheim: Revenue Share, by Business Segment, 2021 and 2022
Figure 40 : Boehringer Ingelheim: Revenue Share, by Region, 2021 and 2022
Figure 41 : Danaher Corp.: Revenue Share, by Business Segment, 2022
Figure 42 : Danaher Corp.: Revenue Share, by Region, 2022
Figure 43 : Dexcom Inc.: Annual Revenue, 2019-2021
Figure 44 : Dexcom: Revenue Share, by Region/Country, 2022
Figure 45 : Dexcom: Revenue Share, by Sales Channel, 2022
Figure 46 : Johnson & Johnson: Financials, 2017-2021
Figure 47 : Johnson & Johnson: Revenue Share, by Country/Region, 2021
Figure 48 : Johnson & Johnson: Revenue Share, by Segment, 2021
Figure 49 : Lilly: Total Sales Share, by Product Segment, 2022
Figure 50 : Medtronic: Financials, 2015-2022
Figure 51 : Medtronic: Revenue Share, by Country/Region, 2022
Figure 52 : Medtronic: Revenue Share, by Key Disease Segment, 2022
Figure 53 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2022
Figure 54 : Merck & Co. Inc.: Revenue Share, by Region/Country, 2022
Figure 55 : Novartis: Revenue Share, by Business Segment, 2022
Figure 56 : Novartis: Total Revenue Share, by Region/Country, 2022
Figure 57 : Novo Nordisk: Revenue Share, by Region, 2022
Figure 58 : Novo Nordisk: Revenue Share, by Business Segment, 2022
Figure 59 : Qiagen: Total Revenue, 2020-2022
Figure 60 : Qiagen: Market Share, by Product Type, 2022
Figure 61 : Roche: Revenue, by Country/Region, 2022
Figure 62 : Sanofi: Net Sales Share, by Business Segment, 2022
Figure 63 : Sanofi: Net Sales Share, by Region/Country, 2022
Figure 64 : Siemens Healthineers AG: Total Revenue, 2020-2022
Figure 65 : Siemens Healthineers AG: Market Share, by Business Segment, 2022
Figure 66 : Thermo Fisher Scientific Inc.: Annual Revenue, 2020-2022
Figure 67 : Thermo Fisher Scientific Inc.: Market Share, by Business Segment, 2022